• HCMV-Induced AKT Inactivation via IRS1 Destabilization Uncov

  2026-06-13

  This study reveals how human cytomegalovirus (HCMV) inactivates the AKT kinase by destabilizing insulin receptor substrate proteins, particularly IRS1, through the viral protein UL38. These findings provide new mechanistic insights into viral manipulation of host cell signaling, which is critical for understanding both viral replication strategies and host cell responses.

• AR Heterogeneity Drives Divergent Therapy Responses in Prost

  2026-06-12

  This study establishes that heterogeneity in androgen receptor (AR) expression among prostate cancer cells underlies distinct responses to castration and antiandrogen therapies like enzalutamide. By linking AR expression patterns to therapeutic sensitivity, the work identifies BCL-2 as a key target and forms a foundational basis for developing precision treatments for castration-resistant prostate cancer.

• Deracoxib in Translational Inflammation Assays: Protocols, P

  2026-06-12

  Explore how Deracoxib, a selective COX-2 inhibitor, advances inflammation assay precision and translational research. This article reveals protocol nuances, cross-talk with NO and apoptosis pathways, and novel practical guidance for advanced pain and cancer biology models.

• Cholecystokinin Octapeptide Ammonium: Workflows & Assay Inno

  2026-06-11

  Cholecystokinin octapeptide ammonium (CCK-8 ammonium) unlocks advanced modeling of neurobehavioral and immunometabolic processes through precise receptor targeting and rigorously validated protocols. Leverage its well-characterized solubility, signaling, and dosing parameters to optimize experiments in zebrafish, neuronal, and cardiometabolic research.

• Quizartinib (AC220): Advancing FLT3 Inhibition Workflows in

  2026-06-11

  Quizartinib (AC220) empowers acute myeloid leukemia (AML) studies with selective FLT3 inhibition and robust in vivo efficacy. This article delivers stepwise protocols, troubleshooting, and practical insights for leveraging Quizartinib in FLT3 signaling and resistance modeling, integrating the latest reference breakthroughs.

• Strategic Bcl-2 Inhibition: Venetoclax and Beyond in NHL & A

  2026-06-10

  This thought-leadership article explores the mechanistic and translational frontiers of ABT-199 (Venetoclax), emphasizing its role as a potent, selective Bcl-2 inhibitor in hematologic malignancy research. It integrates recent insights on combinatorial strategies, practical experimental guidance, and translational research implications, offering a strategic framework that moves beyond standard product-centric narratives.

• Norovirus Hijacks NINJ1 for Selective Secretion of Viral NS1

  2026-06-10

  This study reveals that murine norovirus strategically co-opts the host membrane protein NINJ1 to enable selective secretion of its NS1 protein, distinguishing this process from the bulk release of damage-associated molecules during cell death. The findings clarify the mechanism of unconventional viral protein secretion and identify NINJ1 as a selective regulator, offering new avenues for research in host-pathogen interactions and cell death signaling.

• Targeting IKK-2: TPCA-1 and the Future of Translational Infl

  2026-06-09

  This thought-leadership article explores the mechanistic, experimental, and translational impact of TPCA-1—a highly selective IKK-2 inhibitor—on NF-κB-driven inflammation, with a strategic focus for researchers modeling complex disease states such as septic acute kidney injury and rheumatoid arthritis. Integrating recent advances in NF-κB/miR-202-5p/HMGB2 signaling, the article bridges preclinical insights and practical guidance, clearly distinguishing its scope from conventional product summaries and offering a forward-looking perspective on leveraging TPCA-1 in next-generation translational workflows.

• MALAT1 Modulates PCT Expression in Sepsis via miR-125b/STAT3

  2026-06-09

  This study uncovers how the long noncoding RNA MALAT1 upregulates procalcitonin (PCT) expression in sepsis by sponging miR-125b and activating STAT3. These findings clarify the molecular control of a key sepsis biomarker, suggesting new targets for diagnosis and intervention.

• PEO Chain Density and Uremic Toxin Adsorption in Kidney Dise

  2026-06-08

  This study systematically evaluates how the density of end-tethered methoxy-PEO chains on gold surfaces influences the adsorption of uremic toxins, such as 4-ethylphenyl sulfate. The findings reveal that toxin-surface interactions are dictated more by molecular structure than concentration, informing the design of low-fouling biomaterials for use in chronic kidney disease.

• Lopinavir (ABT-378) Identified as MERS-CoV Inhibitor in FDA

  2026-06-08

  de Wilde et al. conducted a systematic screen of FDA-approved drugs and discovered that Lopinavir (ABT-378), among four small molecules, inhibits MERS-CoV replication at low micromolar concentrations in cell culture. This finding highlights the potential for repurposing HIV protease inhibitors for emerging coronavirus research and provides a framework for rapid-response antiviral studies.

• Batimastat (BB-94): Precision MMP Inhibition in Experimental

  2026-06-07

  Batimastat (BB-94) empowers researchers with robust, selective matrix metalloproteinase inhibition, enabling reproducible dissection of proteolytic signaling in cancer and neurobiology. The latest reference study reveals how targeted MMP blockade shapes BDNF processing at neuromuscular junctions, opening new avenues for synaptic and oncology research.

• ROS-Degradable Lipid Nanoparticles Enable Tumor-Selective mR

  2026-06-06

  This study introduces a combinatorial library of ROS-degradable lipid nanoparticles that enable selective mRNA delivery and expression in tumor cells. By exploiting the elevated intracellular ROS in cancer, the work demonstrates enhanced antitumor efficacy and opens avenues for precision mRNA therapeutics.

• Diclofenac: High-Purity Non-Selective COX Inhibitor for Rese

  2026-06-05

  Diclofenac is a non-selective cyclooxygenase inhibitor prized for its high purity and robust inhibition of prostaglandin synthesis. It is widely used in inflammation and pain signaling pathway research, including advanced intestinal organoid models. APExBIO supplies Diclofenac with validated quality for reproducible anti-inflammatory drug research.

• Asunaprevir (BMS-650032): Translational Leverage in HCV Rese

  2026-06-05

  This article provides translational researchers with mechanistic insights and actionable strategies for deploying Asunaprevir (BMS-650032) in hepatitis C virus (HCV) research. It explores the compound's broad inhibitory profile, delineates protocol nuances, contextualizes its impact within the evolving antiviral landscape, and bridges learnings from epigenetic oncology to inform future directions. APExBIO's Asunaprevir is positioned as a critical tool for those striving to advance HCV biology and therapeutic innovation.

14859 records 1/991 page Next 12345 下5页 Last page